



HYPERTENSIVE DISORDERS OF PREGNANCY 2.0

A. Definitions/terminology:

1. Hypertension

If two systolic BP ≥ 140 mmHg taken 4 hours apart

If two diastolic BP ≥ 90 mmHg taken 4 hours apart

A single systolic BP ≥ 160 mmHg

A single diastolic BP ≥ 110 mmHg

Standard for measurement of BP

- Use machines validated for use in pregnancy
 - The machine used in South African clinical trials is recommended i.e., the CRADLE VITAL SIGNS ALERT (VSA)
 - Machines should be regularly calibrated
 - Machine must be robust.
- BP to be taken in the sitting position with legs uncrossed and in a relaxed position. The arms should be free of clothing, and arm supported so the cuff is at the level of the heart.
- If the MUAC > 33 cm, a larger cuff size should be used. Current machines available with 2 sizes for adults i.e., adult and obese.

2. Pre-hypertension

- Blood pressure of 130-139/85-89 mmHg
- Repeat blood pressure after rest (30min – 2 hours), if still pre-hypertensive review in 3 – 7 days otherwise normal follow-up


3. Pre-eclampsia (PE)

- A syndrome of new onset of hypertension and either proteinuria or end-organ dysfunction most often after 20 weeks of gestation in a previously normotensive woman and resolving within 6 weeks after delivery. Eclampsia is diagnosed when seizures occur.

4. Gestational hypertension (GH)

- Elevated blood pressure (BP $> 140/90$ mmHg) first detected after 20 weeks of gestation in the absence of proteinuria or other features of organ dysfunction in a previously normotensive woman.

It is very important to distinguish gestational hypertension from pre-eclampsia which has a different course and prognosis



5. Chronic Hypertension

- Pre-existing hypertension (BP > 140/90mmHg) that antedates pregnancy and is present before 20 weeks of gestation.

6. Pre-eclampsia (PE) superimposed on existing hypertension

- This occurs in a woman with chronic hypertension who falls pregnant then develops worsening hypertension with new onset of proteinuria or other features of organ dysfunction consistent with pre-eclampsia,
- In the absence of pre-existing proteinuria, new-onset proteinuria in the setting of a rise in blood pressure is sufficient to diagnose superimposed PE.

7. Proteinuria

- Anything more than trace proteinuria warrants investigation
- ≥ 0.3g total protein in a urine specimen collected over 24 hours or

- Urinary protein/creatinine ratio ≥ 0.3

8. Unclassified hypertension

- Hypertension in a patient who is seen for the first time after 20 weeks of gestation

B. Screening for and prevention of Preeclampsia

Blood pressure and dipstick urinalysis must be performed at every antenatal clinic visit to allow early diagnosis.

First trimester screening and preventative therapy for patients at risk of PE can reduce the incidence of PE and more especially early-onset PE.

Calcium supplementation (1000mg elemental Ca⁺⁺) should be given to all pregnant women, with a 2-hour interval between calcium and Iron ingestion, starting at any gestation but preferably as early as possible

Low-dose Aspirin (150mg at night) for women at increased risk of PE is best commenced at 12w (or soonest thereafter) and continued until 36w of pregnancy.

1. Risk assessment based on patient history and demographics

RCOG/NICE guidelines and also the South African National Department of Health recommend risk-factor-based screening (table 1) all women with ≥ 1 high risk factor or ≥ 2 moderate risk factors qualify for low-dose aspirin.

Table 1. Risk factors for preeclampsia

High Risk Factors	Moderate Risk factors
Hypertensive disease during a previous pregnancy	First pregnancy
Chronic kidney disease	Age ≥ 40 years
Autoimmune disease such as SLE or antiphospholipid syndrome	Pregnancy interval > 10 years
Type 1 or 2 Diabetes	Family History of PE
Chronic hypertension	Multiple Pregnancy
Assisted reproduction (IVF etc.)	
Maternal BMI $> 35\text{kg/m}^2$	

This form of screening is only recommended if it is not possible to use the Fetal Medicine Foundation (FMF) online tool (see No. 2. below).

2. Multimodal screening for PE using the FMF Algorithm

Risks are derived from: maternal history/characteristics, biophysical measurements (mean uterine artery PI and mean arterial pressure (MAP)) and serum biomarker levels (PLGF or PAPP-A when PLGF is not available).

Data is entered on the FMF website and calculation of risk will be provided based on built-in algorithms.

- **MAP must be done according to the FMF protocol with automated equipment that must be calibrated annually (protocol available on FMF website).**
- **Uterine artery Doppler PI only to be used if operator accredited by FMF (protocol available on FMF website).**

<https://fetalmedicine.org/research/assess/preeclampsia/first-trimester>

A positive screen is a calculated risk of PE > 1 in 100.

C. Management

N.B. Taking a full history and awaiting results of all investigations before intervention is only advised if the patient is stable, has non-severe hypertension and no features to suggest severe PE or eclampsia.

1. Normotensive with proteinuria on dipstick analysis

- Outpatient management
- Urine specimen for MC&S
- Urine for PCR or quantify 24hr protein excretion
- If significant proteinuria: consult physician
- Check BP twice weekly if all normal

2. Non-severe Hypertension and asymptomatic at $\geq 20w$ (BP $\geq 140/90$ and $< 160/110$ mmHg)

- Urine dipstick analysis
- Quantify 24hr urine protein excretion/U-PCR
- Start Methyldopa (HyPoTone®) 500mg 8hrly
- Do Hb, Platelet count, s-Cr, AST/ALT
- Urine specimen for MC&S
- Umbilical artery Doppler
- If gestational hypertension is diagnosed and BP is well controlled, continue anti-hypertensive therapy and plan delivery at 38 weeks if all remains well in the interim
- If PE confirmed then:
 - Admit patient
 - If remote from viability the option of TOP can be discussed
 - If the fetus is viable and $\leq 33w6d$ and no indication for immediate delivery, the offer of expectant management can be made which includes:
 - In-patient management in a facility with 24hr OT, high care and NICU
 - A course of steroids to enhance fetal lung maturity +/- MgSO₄ for fetal neuroprotection according to institutional protocol
 - 4 hrly BP monitoring once stable
 - 6 hrly CTG monitoring
 - Twice weekly Hb, Platelet count, s-Cr, AST/ALT

- Delivery end-points: patient declines expectant management, suspected fetal compromise, abruptio placentae, worsening renal function, HELLP syndrome, patient becomes symptomatic or develops eclampsia, uncontrolled hypertension, pulmonary oedema or any other obstetric indication.
- If all remains well in the interim, delivery can be considered from 34w onwards

3. Hypertension with symptoms or severe features

- Call obstetrician
- Admit in High care unit and nurse in left lateral
- Insert urinary catheter and IV line
- Administer IV Ringers lactate (total volume of IV fluid administered should not exceed 80mls/hr)
- Start Magnesium Sulphate (see number 5 below)
- Control BP – if non-severe see number 2 above and if severe see number 4 below
- Perform an ultrasound (if indicated) or assess clinically to determine fetal viability, EFW (Estimated Fetal Weight) and liquor volume and, if possible and indicated, umbA RI
- If GA \geq 34/40 or EFW \geq 2200g expedite delivery
- If GA \geq 26/40 and $<$ 34/40, administer course of steroids to enhance fetal lung maturity
- If patient is stabilised, offer expectant management if $<$ 34 weeks and eligible (see number 2 above)
- In cases of hypertension or PE with severe features, only monitor the fetus once the woman is stable
- Always remember to exclude molar pregnancy and multiple pregnancy

4. Acute severe hypertension (DBP \geq 110mmHg and or SBP \geq 160mmHg)

- Administer Nifedipine (Adalat®) 10mg per os immediately
- Start maintenance therapy with Nifedipine (Adalat XL®) 30-60mg BD orally (maximum 120mg/day)
- Aim for DBP \leq 110 and SBP \leq 160mmHg
- If BP is still high after 30 minutes, repeat Nifedipine (Adalat®) 10mg orally every 30 minutes, for a maximum of three dosages or until BP $<$ 160/110mmHg (contraindication: tachycardia $>$ 120 bpm, unable to swallow, cardiac lesion).
- If after 30 minutes BP is still high then give Labetalol (Trandate®) 20, 40, 80, 80 and 80mg (max 300mg) as bolus doses at 10 minute intervals, checking BP every 10 minutes until BP $<$ 160/110mmHg. Contra-indications: patients with asthma and ischaemic heart disease. If BP monitoring is not achievable at 10 minute intervals then patient should be transferred to ICU for a Labetalol infusion.
- *NB Mother receiving Labetalol must be closely monitored with continuous ECG and BP monitoring if possible, and adequate nursing staff cover*

5. Magnesium Sulphate regimen

- Loading dose: Magnesium Sulphate (MgSO₄) 4g in 200ml Normal Saline 0.9% to be administered over 20-30 minutes.

- Maintenance dose: Magnesium Sulphate 4g in 200ml Normal Saline 0.9% to be administered at 1g per hour for 24 hours **OR** 5gm 4-hourly IMI for 24 hours.
- Post- partum: Continue Magnesium Sulphate infusion until 24 hours post-delivery or since the last fit.
- Contra-indications: Myasthenia Gravis

Observation requirements

- 1/2 Hourly BP and Pulse
- Indwelling urinary catheter
- Hourly urine output, if < 30ml/hr discontinue Magnesium Sulphate infusion and manage cause of oliguria
- Hourly Respiratory rate
- Check patella reflexes before commencing each bag of MgSO₄, do not start new bag if reflexes absent
- Temperature check every 4 hours

Symptoms of overdose:

- Extreme thirst
- Hot flushes
- Decreased respiratory rate
- Dulled or absent reflexes
- Decreased urinary output
- Feeling weak and lethargic

Antidote: Calcium Gluconate 10%, 10ml IVI slowly over 2 – 3 minutes

N.B. If patient has further convulsions during maintenance, give further 2g MgSO₄ IV slowly.

6. Drug options for maintenance anti-hypertensive therapy

- Nifedipine (Adalat® XL) – 30mg once daily to a maximum dose of 60mg twice daily.
- Methyldopa (HyPoTone®) – 500mg 8 hourly to maximum dose of 750mg 8 hourly
- Hydrallazine – 25mg 8 hourly to a maximum dose of 50mg 8hrly

7. Post- partum and future pregnancies

- All patients with PE must be monitored in a designated high care unit/high dependency area post-delivery for at least 24hours and longer if there were any complications
- Stop Methyldopa and start medication patient was using prior to conception if she had chronic hypertension else consider enalapril, hydrochlorothiazide and/or amlodipine if patient is still requiring anti-hypertensive therapy
- Ensure the provision of reliable contraception and counsel on planned future pregnancies if desired.
- Post-partum visit must be done within 10 days of discharge

References

1. Daniel L. Rolnik, M.D., David Wright, Ph.D., Liona C. Poon, M.D., et al et al et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377:613-622.
2. Eclampsia and Severe Preeclampsia: ESMOE
3. O’Gorman N, Wright D, Poon LC, et al. Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison to NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017;49:756-760
4. Adam, S. Soma-Pillay, P. Obstetric Essentials. 2018. 3rd Edition. University of Pretoria. p57
5. Moodley J, Soma-Pillay P, Buchmann E, Pattinson R. Hypertensive disorders in pregnancy: 2019 National guideline. S Afr Med J. 2019;109(9):12723.
6. A.L. Tranquilli, G. Dekker, L. Magee, J. Roberts, B.M. Sibai, W. Steyn, G.G. Zeeman and M.A. Brown. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 2014-04-01, Volume 4, Issue 2, Pages 97-104

Authorship

These guidelines were drafted by a clinical team from Mediclinic and were reviewed by a panel of experts from SASOG and the BetterObs clinical team and revised buy the Betterobs scientific subcommittee in 2022. All attempts were made to ensure that the guidance provided is clinically safe, locally relevant and in line with current global and South African best practise. Succinctness was considered more important than comprehensiveness.

All guidelines must be used in conjunction with clinical evaluation and judgement; care must be individualised when appropriate. The writing team, reviewers and SASOG do not accept accountability for any untoward clinical, financial or other outcome related to the use of these documents. Comments are welcome and will be used at the time of next review.

Released on date: 2022 08 01

Disclaimer:

This document has been developed by interdisciplinary healthcare teams utilising the best available evidence and resources believed to be accurate and current at the time of release. They are intended to provide general advice and guidance on which to base clinical decisions. SASOG takes no responsibility for matters arising from changed circumstances or information that may have become available after issued. They must not be solely relied on or used as a substitute for assessing the individual needs of each patient.